The innovative research of Seven and Eight Biopharmaceuticals Inc. is helping to redefine immunotherapy as a gateway to more effective treatments and cures for cancers and inflammatory diseases.
Here on our Research and Pipeline page, you can view the status of ongoing clinical trials. At any given time, our team of scientists is working on multiple programs, all in various phases of research and development. The overarching goal of this research is the development of a pipeline based on TLR7/8 biology combined with checkpoint inhibitors of PD-1/PD-L1. The rationale for clinical use of our TLR7/8 agonists is to activate both the innate and adaptive immune responses thereby expanding the anti-tumor immune activities when combined with anti-PD-1/PD-L1 mAb.